key: cord-0747346-q6eqrep8
authors: Oliveira, Eduardo A.; Simões e Silva, Ana Cristina; Oliveira, Maria Christina L.; Colosimo, Enrico A.; Mak, Robert H.; Vasconcelos, Mariana A.; Miranda, Debora M.; Martelli, Daniella B.; Silva, Ludmila R.; Pinhati, Clara C.; Martelli-Júnior, Hercílio
title: Comparison of the first and second waves of the COVID-19 pandemic in children and adolescents in a middle-income country: Clinical impact associated with SARS-CoV-2 gamma lineage
date: 2022-01-11
journal: J Pediatr
DOI: 10.1016/j.jpeds.2022.01.001
sha: edc4949f334a85cbf089eebda0907b32f3d4d648
doc_id: 747346
cord_uid: q6eqrep8

OBJECTIVE: To evaluate the severity and clinical outcomes of the SARS-CoV-2 gamma variant in children and adolescents hospitalized with COVID-19 in Brazil. STUDY DESIGN: In this observational retrospective cohort study, we performed an analysis of all 21,591 hospitalized patients aged < 20 years with confirmed SARS-CoV-2 infection registered in a national database in Brazil. The cohort was divided into two groups according to the predominance of SARS-CoV-2 lineages (WAVE1, n = 11,574 and WAVE2, n = 10,017). The characteristics of interest were age, sex, geographic region, ethnicity, clinical presentation, and comorbidities. The primary outcome was time to death, which was evaluated by competing-risks analysis, using cumulative incidence function. A predictive Fine-Gray competitive risks model was developed based on WAVE1 cohort with temporal validation in WAVE2 cohort. RESULTS: Children and adolescents admitted during the second wave had significantly more hypoxemia (52.5% vs. 41.1%, P < 0.0001), admission to ICU (28.3% vs. 24.9%, P < 0.0001), and needed more non-invasive ventilatory support (37.3% vs. 31.6%, P < 0.0001). The in-hospital deaths and death rates in the first and second waves were respectively 896 (7.7%) and 765 (7.6%) (P=0.07). The prediction model of death included age, ethnicity, region, respiratory symptoms, and comorbidities. In the validation set (WAVE2), the C statistics was 0.750 (95%CI, 0.741 to 0.758, P < 0.0001). CONCLUSIONS: This large national study found a more severe spectrum of risk for pediatric patients with COVID-19 caused by the Gamma variant. However, there was no difference regarding the probability of death between the waves.

Concomitantly, Brazil experienced a severe second wave of cases related to a failure to mitigate the spread of this variant of concern 2 . The P.1 (gamma) lineage is characterized by the combination of K417T, E484K, and N501Y substitutions in spike protein 3 Children usually present an asymptomatic or mild course, with a much lower risk from severe COVID-19 than any other age groups 5, 6 . Nevertheless, a relatively low proportion of children might be at risk for severe disease and death 7, 8 . We previously characterized the first 11,613 pediatric hospital admissions for COVID-19 in Brazil 9 . In the present study, we focused our analysis on children and adolescents (aged <20 years) admitted in the second wave, concomitantly with the expansion and dominance of the gamma variant, with the aim of comparing the clinical outcomes between distinct J o u r n a l P r e -p r o o f periods. In addition, we developed a clinical prediction model of COVID-19 relateddeath in pediatric age.

We performed a retrospective cohort study including all hospitalized pediatric cases recorded in the Influenza Epidemiological Surveillance Information System (SIVEP-Gripe) 10 . Detailed information regarding this database, including reporting form and data dictionary, codes, and all de-identified data, are publicly available at https://opendatasus.saude.gov.br/dataset/bd-srag-2020. Additional information regarding SIVEP-Gripe and the steps of the data retrieve are provided in the Appendix as supplementary material (S. 1) We included all consecutively registered patients, aged < 20 years, with a positive quantitative RT-PCR (RT-qPCR) test result for SARS-CoV-2 who had been admitted to hospital. The detailed information about included and excluded cases were displayed in flowcharts ( Figure 1 ; available at www.jpeds.com). For the purpose of analysis, we integrated both datasets into a unique database and the cases were stratified into two groups, WAVE1 (44 epidemiological weeks from February 16, 2020 to December 31, 2020) and WAVE2 (19 epidemiological weeks from January 01, 2021 to May 29, 2021 ).

In addition, on May 29, 2021 we updated, the outcomes of interest for pediatric patients admitted at WAVE1.

Covariates and definitions Clinical, demographic, and epidemiological data recorded in SIVEP-gripe are described elsewhere 9 . The clinical course of the disease was reported in terms of respiratory support (none, noninvasive oxygen support, and invasive ventilation), admission to intensive care unit (ICU), discharge, death, and ongoing clinical situation. Detailed information regarding variables used in the study is provided in the Appendix as supplementary material (S.2)

The primary outcome was time until death (in-hospital-mortality). The survival time was defined from the day of admission until the event (death or discharge).

The sample comprised all pediatric patients (aged < 20 years) with COVID-19 registered in the SIVEP-Gripe between epidemiological weeks 08, 2020 to 19, 2021, divided into two groups (WAVE1 and WAVE2). We used medians and IQRs or means and SDs to summarize continuous variables, and calculated frequencies and proportions for categorical variables. For comparison of medians and proportions, it was used respectively the chi-square and the Mann-Whitney U tests. Mortality was evaluated by competing risks analysis, using cumulative incidence function (CIF) 11 . Discharge was analyzed as a competing event in the competing-risks analysis. Complete data were not available for all variables, especially ethnicity, symptoms at presentation, and J o u r n a l P r e -p r o o f comorbidities. We carried out multiple imputation using all predictors plus the CIF for the primary outcome. This involves creating multiple copies of the data and imputing the missing values for each dataset with sensible values randomly selected from their predicted distribution. Ten imputed were generated using the multiple imputation chain equations (MICE) package of the software R. We combined the results from analyses on each of the imputed values using Rubin's rules to produce estimates and confidence intervals that incorporate the uncertainty of imputed values 12, 13 . For those cases with missing data on a given symptom or comorbidity, we assumed the clinical condition to be absent. Detailed information regarding the management of missing data is provided in supplementary material (S.2, Page 6)

We developed a clinical prediction model and a points-based risk-scoring system 

We accessed data in SIVEP-Gripe, which are already de-identified and publicly available. Following ethically agreed principles on open data, this analysis did not require ethical approval in Brazil. We reported our findings following the guideline STROBE for observational cohort studies 15 . J o u r n a l P r e -p r o o f

A total of 21,591 cases <20 years of age with laboratory-confirmed SARS-CoV-2 infection were hospitalized during the analyzed pandemic period. The incident cases and deaths over time are shown in Figure 2 (available at www.jpeds.com). In the WAVE1, 11,574 cases (53.6%) were hospitalized with an average number of 263 cases per week, while in the WAVE2, 10,017 cases (46.4%) were admitted to the hospital, with an average of 527 cases per week. In-hospital deaths and death rates in the first and second waves were respectively 896 (7.7%) and 765 (7.6%).

The clinical and demographic characteristics of the cohort stratified according to the waves are shown in Table I . Compared with the first wave, hospitalized children in the second wave were younger with a larger proportion of infants < 2 years. There was also higher proportion of pediatric patients from the richest regions (South and Southeast) and of white ethnicity. Considering clinical presentation, cases hospitalized in the second wave had more respiratory symptoms, including cough, respiratory distress, and dyspnea. Overall, regarding pre-existent conditions, children from the second wave were less affected by chronic conditions. J o u r n a l P r e -p r o o f In relation to clinical outcomes, children admitted in the second wave had a significantly larger proportion of hypoxemia (52.5% vs. 41.1%), needed more admission to ICU (28.3% vs. 24.9%), and used more non-invasive ventilatory support (37.6% vs. 31.6%).

Of note, in overall, 406 children who needed invasive ventilatory support were not admitted to an ICU (with similar rates for both waves). Of these, 155 (38.2%) died, a death rate about 5 times compared with the entire cohort.

The overall estimated CIFs for death and discharge for both waves are shown in Figure 3 (available at www.jpeds.com). By the competing-risk survival analysis, no significant difference in the risk of fatal outcome between the periods was found. However, at the time of the analysis, 517 children (4.5%) admitted during WAVE1 were still in-hospital with an ongoing clinical condition. For the WAVE2, this figure was 1,371 (13.7%) cases. Moreover, among these still hospitalized patients, 13% in WAVE1 and 21.9% in WAVE2 were in invasive ventilatory support at the time of analysis.

The estimated probability of fatal outcome for children admitted in the WAVE1 was 4.8% during the first 10 days of hospitalization, 6.7% during the first 20 days and 8.1%

at the end of follow-up. The respective findings in WAVE2 were 4.4%, 7%, and 9.7% (P = 0.07). Regarding hospital discharge, the respective rates in WAVE1 were 54%, 78%, and 92% and in WAVE 2 were 54.5%, 79.5%, and 90% (P = 0.107).

The univariate competing-risk survival analysis for the risk of death regarding the clinical and demographic characteristics of this cohort is shown in Table II (available at www.jpeds.com). Using the Fine and Gray model-to-model mortality, the following variables were significantly associated with the fatal outcome: age (infants and adolescents), regions (North and Northeast), ethnicity (Black /Brown and Indigenous), and respiratory symptoms (respiratory distress, dyspnea, and oxygen saturation < 95%).

Presence of any comorbidity, number of comorbidities and all the main specific preexisting medical conditions analyzed, except for asthma, increased risk of death in univariable analysis.

After adjustment by the competing-risk multivariate survival analysis, based on the multiple imputation results, all covariates were retained as significant predictors of COVID-19-related death as shown in Table III . A risk weighting for each covariate was then derived from the estimated regression coefficients, which were multiplied by 10 and rounded to the nearest integer (Table III) . A total risk score was calculated as the sum of these weightings for the variables. A risk score was calculated for each patient by adding up the obtained points. The risk score ranged from -1 for patients from region Central-West without any risk factors to 57 points with a median of 16 (IQR, 10 -22) among children admitted in the WAVE1. Lastly, the prognostic risk score was divided 

In this large observational cohort study, we compared the dynamics of two distinct periods of the COVID-19 pandemic in Brazilian pediatric patients using a nationwide database of hospitalized cases. our findings confirmed the higher lethality of SARS-CoV-2 infection in pediatric age in Brazil compared with developed countries, with a death rate of ~7.5% in both waves. This figure is about 60 times greater compared with a death rate of 0.12% (8/6,338) in children and adolescents hospitalized in England 16 . In a previous analysis, we have shown that this disparity in mortality rate was mainly related with socioeconomic and health care inequalities in Brazil 9 . In addition, our analysis has shown that in the second wave, the average number of cases and deaths per

week doubled compared with first period of the pandemic. Consequently, in absolute terms, there was roughly a similar number of cases and deaths in both waves, despite the second wave included much fewer epidemiological weeks. In addition, children and adolescents admitted in the second wave had significantly more hypoxemia, admission to ICU, and needed more non-invasive ventilatory support. Nevertheless, our analysis has shown that no significant difference was found in the case fatality rate between the waves.

Our data suggest that the gamma variant is more transmissible than its precursors and increased the burden of more severe cases, but without affecting the case fatality rate among hospitalized pediatric patients with COVID-19. Nevertheless, the comparison of the death rates between the waves should be interpreted with caution due to a substantial number of ongoing clinical situations in patients admitted in the second wave. In this J o u r n a l P r e -p r o o f regard, Bastos et al 17 , compared the two waves in the adult population in Brazil using the same database. Based on data of about 1,200,000 COVID-19 hospitalizations, the authors also showed that the second wave resulted in an increased burden of severe cases in adults. Of note, unlike our study, they found an increase in in-hospital mortality from 33.1% to 40.6%. For adult populations, this scenario of worse outcomes, possibly related with other variants of concern, was also reported in the second waves of UK 18 and Africa 19 .

Using the pediatric patients admitted in the first wave as a developing cohort and those admitted in the second wave as a validation cohort, we developed a risk prediction model of a fatal outcome with good accuracy and excellent calibration. The risk model showed a moderately high AUC value of 0.756 (95% CI, 0.751 to 0.762). It means that the model ability to discriminate between patients who survived or died during the follow-up was about 75%. Moreover, based on the risk score, children were classified into low-, intermediate-, and high-risk groups, with an excellent agreement between the observed risk and the predicted risk grouped into these three categories.

the prediction model showed that interweaving clinical, epidemiological, and social factors were significantly associated with a higher hazard of death in pediatric age group. Regarding epidemiological factors, age showed a "U" shape with the infants and adolescents at increased risk of death. Accordingly, in a meta-analysis of 57 studies, Harwood et al 21 showed similar findings. The authors found that odds of poor outcomes were 1.6 to 2-fold higher for infants; and teenagers had elevated odds of severe COVID-

Among clinical factors, the negative effect of the presence of any chronic condition was confirmed as previously demonstrated in adults and pediatric cohorts 5, 9, 20 Prediction models to estimate the risk of a poor outcome from COVID-19 can provide helpful assistance for clinical and public policy decision-making 29 . in a systematic review, Wynants et al 30 , reviewed 145 models, of which 23 were for predicting mortality in adults with COVID-19. However, critical appraisal of these models showed high risk of bias. Calibration and external validation, deemed essential before application can be J o u r n a l P r e -p r o o f considered, was rarely done, or reported. We believe that our analysis, based on a robust dataset, allowed us to report a model with calibration and temporal validation, which strengthen the findings of this study. Moreover, the competing-risk survival analysis used in the development of the model precluded another potential bias, i.e., to consider not to have had the outcome patients who did not develop the event of the interest by the end of the study 31 .

Our study has several limitations. In addition to the absence of a representative genomic surveillance in Brazil, various shortcomings of epidemiologic databases should be considered 9 . For instance, there is no link between the cases included in the dataset to the hospital records. Therefore, we had no access to relevant clinical data such as laboratory/imaging results or treatment of the patients. It might be speculated that the performance of the model could have been improved whether we had had access to these data during hospital admission. Furthermore, SIVEP-Gripe contains a considerable amount of missing data. To try to overcome this limitation, we used multiple imputation technique for relevant predictors.

The findings of our study confirm the worse outcome of COVID-19 in developing compared with developed countries. In addition, the results indicate that the second wave of COVID-19 in Brazil, probably related to the gamma variant, resulted in increased morbidity in pediatric patients, but without difference in death rates between the waves. This difference in outcomes and epidemiologic profile presented by the gamma variant may indicate that new variants can lead to changes in the clinical and epidemiologic profile of COVID-19. Monitoring these aspects will be essential to define global public health responses to new variants that may arise. Our study also developed and validated a risk score derived from a prediction model that predicted with accuracy the hazard of death in hospitalized pediatric patients from a developing country.

Currently, as the vaccination programs for adults have been moving forward in a heterogeneous pace around the world, data on children might become the focus for the next steps to control the SARS-CoV-2 infection. In this context, our model may provide insights to elaborate future strategies to mitigate and prevent the consequences of the COVID-19 in pediatric ages.

Surveillance Information System) were systematically collected by these frontline health-care workers. We are extremely grateful to the frontline clinical staff of the Brazilian Public Health System (SUS) who collected these data in challenging circumstances for their invaluable contribution in these difficult times. J o u r n a l P r e -p r o o f 

Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus

Overcoming Brazil's monumental COVID-19 failure: an urgent call to action

The emergence of novel SARS-CoV-2 variant P.1 in Amazonas (Brazil) was temporally associated with a change in the age and sex profile of COVID-19 mortality: A population based ecological study. The Lancet Regional Health -Americas

Resurgence of COVID-19 in Manaus, Brazil, despite high seroprevalence

COVID-19 in children and adolescents in Europe: a multinational, multicentre cohort study

Clinical characteristics of children and young people admitted to hospital with covid-19 in United Kingdom: prospective multicentre observational cohort study

Multisystem Inflammatory Syndrome in Children in New York State

Severe Coronavirus Disease-2019 in Children and Young Adults in the Washington, DC, Metropolitan Region

Clinical characteristics and risk factors for death among hospitalised children and J o u r n a l P r e -p r o o f adolescents with COVID-19 in Brazil: an analysis of a nationwide database

COVID-19 and hospitalizations for SARI in Brazil: a comparison up to the 12th epidemiological week of 2020

Tutorial in biostatistics: competing risks and multi-state models

Dealing with missing predictor values when applying clinical prediction models

Multiple imputation: a primer

Developing points-based risk-scoring systems in the presence of competing risks

The Strengthening the Reporting of Observational Studies in Epidemiology (STROBE) statement: guidelines for reporting observational studies

Risk factors for intensive care admission and death amongst children and young people admitted to hospital with COVID-19 and PIMS-TS in England during the first pandemic year. medRxiv

COVID-19 hospital admissions: Brazil's first and second waves compared

Risk of mortality in patients infected with SARS-CoV-2 variant of concern 202012/1: matched cohort study

The first and second waves of the COVID-19 pandemic in Africa: a cross-sectional study

Factors associated with COVID-19-related death using OpenSAFELY

Which children and young people are at higher risk of severe disease and death after SARS-CoV-2 infection: a systematic review and individual patient meta-analysis

Syndemics and the biosocial conception of health

Social vulnerability as a risk factor for death due to severe paediatric COVID-19

Clinical Characterization and Prediction of Clinical Severity of SARS-CoV-2 Infection Among US Adults Using Data From the US National COVID Cohort Collaborative

Ethnic differences in SARS-CoV-2 infection and COVID-19-related hospitalisation, intensive care unit admission, and death in 17 million adults in England: an observational cohort study using the OpenSAFELY platform

Characterisation of the first 250 000 hospital admissions for COVID-19 in Brazil: a retrospective analysis of nationwide data

Maternal and Neonatal Morbidity and Mortality Among Pregnant Women With and Without COVID-19 Infection: The INTERCOVID Multinational Cohort Study

Association Between Race and COVID-19 Outcomes Among 2.6 Million Children in England

Improving clinical management of COVID-19: the role of prediction models

Prediction models for diagnosis and prognosis of covid-19: systematic review and critical appraisal

Clinical features of COVID-19 mortality: development and validation of a clinical prediction model